Imagine you’re making a batch of cookies, and you need a specific ingredient called spermidine. This ingredient has been shown to affect how well the cookies turn out, but you’re not exactly sure how much you should use. Well, scientists have been studying the effects of spermidine on cognitive function in humans, and their findings suggest that there is a non-linear association between serum spermidine levels and mild cognitive impairment (MCI). It’s like finding the perfect balance of ingredients to make the best cookies! The study included over 3,700 adult participants without dementia, and they found that higher levels of spermidine were associated with a lower risk of MCI. In other words, having more spermidine in your system may be beneficial for your cognitive health. This is exciting news because it means that monitoring spermidine levels could help reduce the incidence of MCI and lessen the burden it places on individuals and society as a whole. So, next time you’re in the kitchen, don’t forget to add a dash of spermidine to your recipe! To learn more about the study, check out the link below!
BackgroundAlthough animal studies show that spermidine (SPD) affects cognitive function, the relevant evidence among humans is limited. We aim to examine the association between serum SPD levels and cognitive performance.Materials and MethodsWe conducted a cross-sectional and longitudinal study including a baseline and one follow-up survey. The baseline survey was conducted from June 2019 to August 2019, while the follow-up survey was conducted from June 2021 to August 2021. We analyzed 3,774 adult participants aged >35 years, who had no history of dementia.ResultsThe mean (SD) age of the participants was 57.4 (9.8) years. Relative to the first tertile, the multivariate-adjusted ORs (95% CIs) of mild cognitive impairment (MCI) for the second and third tertile groups were 0.78 (0.65, 0.93) and 0.80 (0.67, 0.96), respectively. Restricted cubic spline models show that there is a non-linear association between SPD and MCI. In line with cross-sectional findings, the longitudinal study showed that a high SPD concentration may indicate a lower risk of MCI [ORs (95% CIs) for the third tertile of 0.62 (0.39, 0.99)].ConclusionOur findings suggest that SPD is favorable for cognitive function. Monitoring the SPD levels may help reduce the incidence of MCI, hence decreasing the burden of MCI.
Dr. David Lowemann, M.Sc, Ph.D., is a co-founder of the Institute for the Future of Human Potential, where he leads the charge in pioneering Self-Enhancement Science for the Success of Society. With a keen interest in exploring the untapped potential of the human mind, Dr. Lowemann has dedicated his career to pushing the boundaries of human capabilities and understanding.
Armed with a Master of Science degree and a Ph.D. in his field, Dr. Lowemann has consistently been at the forefront of research and innovation, delving into ways to optimize human performance, cognition, and overall well-being. His work at the Institute revolves around a profound commitment to harnessing cutting-edge science and technology to help individuals lead more fulfilling and intelligent lives.
Dr. Lowemann’s influence extends to the educational platform BetterSmarter.me, where he shares his insights, findings, and personal development strategies with a broader audience. His ongoing mission is shaping the way we perceive and leverage the vast capacities of the human mind, offering invaluable contributions to society’s overall success and collective well-being.